197 related articles for article (PubMed ID: 31826955)
1. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Fu X; Pereira R; De Angelis C; Veeraraghavan J; Nanda S; Qin L; Cataldo ML; Sethunath V; Mehravaran S; Gutierrez C; Chamness GC; Feng Q; O'Malley BW; Selenica P; Weigelt B; Reis-Filho JS; Cohen O; Wagle N; Nardone A; Jeselsohn R; Brown M; Rimawi MF; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26823-26834. PubMed ID: 31826955
[TBL] [Abstract][Full Text] [Related]
2. High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Fu X; Pereira R; Liu CC; De Angelis C; Shea MJ; Nanda S; Qin L; Mitchell T; Cataldo ML; Veeraraghavan J; Sethunath V; Giuliano M; Gutierrez C; Győrffy B; Trivedi MV; Cohen O; Wagle N; Nardone A; Jeselsohn R; Rimawi MF; Osborne CK; Schiff R
Cell Rep; 2023 Aug; 42(8):112821. PubMed ID: 37467106
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance.
Zhang X; Zhang Q; Liu G
Front Genet; 2022; 13():992444. PubMed ID: 36204307
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
6. FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer.
Seachrist DD; Anstine LJ; Keri RA
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680352
[TBL] [Abstract][Full Text] [Related]
7.
Arruabarrena-Aristorena A; Toska E
Mol Cell Oncol; 2021; 8(3):1891831. PubMed ID: 34027035
[TBL] [Abstract][Full Text] [Related]
8. HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.
Jarman EJ; Ward C; Turnbull AK; Martinez-Perez C; Meehan J; Xintaropoulou C; Sims AH; Langdon SP
Breast Cancer Res; 2019 Jan; 21(1):10. PubMed ID: 30670058
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.
Liu Y; Yu K; Kong X; Zhang K; Wang L; Zhang N; Chen Q; Niu M; Li W; Zhong X; Wu S; Zhang J; Liu Y
Sci Adv; 2023 Aug; 9(33):eadg7112. PubMed ID: 37595040
[TBL] [Abstract][Full Text] [Related]
11. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
12. Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2α in invasive breast cancer cells.
Fuady JH; Gutsche K; Santambrogio S; Varga Z; Hoogewijs D; Wenger RH
Oncotarget; 2016 May; 7(21):31153-65. PubMed ID: 27105516
[TBL] [Abstract][Full Text] [Related]
13. High Throughput Chemical Screening Reveals Multiple Regulatory Proteins on FOXA1 in Breast Cancer Cell Lines.
Wang S; Singh SK; Katika MR; Lopez-Aviles S; Hurtado A
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572598
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
[TBL] [Abstract][Full Text] [Related]
15. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.
Fu X; Huang C; Schiff R
Breast Cancer Res; 2011 Apr; 13(2):307. PubMed ID: 21575280
[TBL] [Abstract][Full Text] [Related]
16. A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPR
Yan Y; He M; Zhao L; Wu H; Zhao Y; Han L; Wei B; Ye D; Lv X; Wang Y; Yao W; Zhao H; Chen B; Jin Z; Wen J; Zhu Y; Yu T; Jin F; Wei M
Cell Death Differ; 2022 Sep; 29(9):1769-1789. PubMed ID: 35301432
[TBL] [Abstract][Full Text] [Related]
17. Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
Padró M; Louie RJ; Lananna BV; Krieg AJ; Timmerman LA; Chan DA
BMC Cancer; 2017 Mar; 17(1):203. PubMed ID: 28320353
[TBL] [Abstract][Full Text] [Related]
18. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
20. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
